BioRegenx, Inc.
BRGX
$0.01
$0.000.00%
OTC PK
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 10.53% | -24.06% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 10.53% | -24.06% | |||
| Cost of Revenue | 16.44% | -17.81% | |||
| Gross Profit | 9.25% | -25.23% | |||
| SG&A Expenses | -28.19% | 27.48% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -20.19% | 15.52% | |||
| Operating Income | 76.36% | -2,378.82% | |||
| Income Before Tax | 97.41% | -1,162.78% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 97.41% | -1,162.78% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 97.41% | -1,162.78% | |||
| EBIT | 76.36% | -2,378.82% | |||
| EBITDA | 78.69% | -4,528.21% | |||
| EPS Basic | 100.00% | -1,000.00% | |||
| Normalized Basic EPS | 100.00% | -100.00% | |||
| EPS Diluted | 100.00% | -1,000.00% | |||
| Normalized Diluted EPS | 100.00% | -100.00% | |||
| Average Basic Shares Outstanding | 0.78% | 0.08% | |||
| Average Diluted Shares Outstanding | 0.78% | 0.08% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||